Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Gen... (Stockfleth of the Department of Dermatol...)

HOME >> MEDICINE >> TECHNOLOGY

Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts

Date:9/22/2008

Stockfleth of the Department of Dermatology, Skin Cancer Center Charite, Universitatsmedizin Berlin will oversee the German study activities specifically.

About Ano-Genital Warts

Ano-genital warts result from HPV infection of the external genitalia, and can manifest as outwardly visible growths of varying sizes and shapes in both men and women. Each year in the United States alone, there are over 750,000 new cases of ano-genital warts.

About Topical Interferon Alpha-2b

Interferon Alpha-2b is an immune system modulator that is active against a variety of HPV-induced lesions. Interferon Alpha-2b is thought to function by triggering an antiviral response within infected cells, by activating certain intracellular enzymes which cause degradation of viral RNA, and by mobilizing the body's natural immune system to destroy the infected cells. Interferon Alpha-2b has been widely used commercially as a treatment for ano-genital warts caused by HPV, but is not generally favoured due to the fact that conventional administration requires painful intradermal injection by a medical professional. Furthermore, intradermal injection is restricted to visible lesion administration, while HPV infection is often characterized by both visible and non-visible (i.e. sub-clinical) lesions. Helix's Topical Interferon Alpha-2b is expected to offer a safe, discreet, self-administered, pain-free therapy that can be broadly applied across the entire affected tissue area. Helix anticipates that this will prove highly advantageous not only from a patient compliance perspective, but also from an efficacy standpoint.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha- 2b and
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units

Post Your Comments:

(Date:5/22/2013)... 22, 2013 Upsher-Smith Laboratories, Inc. ... its global Phase III clinical trial for ... for the management of epilepsy in adults, ... is specifically engineered to provide convenient once-daily ... levels observed with currently available treatment options. ...

(Date:5/22/2013)... 22, 2013 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the following conferences. , ... date: Wednesday May 29, 2013 , Presentation time: 12:00 ... Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of these ...

(Date:5/22/2013)... REHOVOT, Israel , May 22, 2013 ... a leading developer and provider of microRNA-based molecular diagnostics, ... President and Chief Executive Officer of Rosetta Genomics, will ... Conference taking place from June 3-6, 2013 in New ... Tuesday, June 4 th at 2:00 p.m. Eastern ...

Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4 Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3

[0] Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures [0] Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences [0] Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference

... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... Technology platforms, key players, and early pipeline ... Therapeutic vaccines promise a ...

... Nov. 8, 2010 Reportlinker.com announces that ... in its catalogue: Opportunities ... growth in key regions and therapeutic areas ... The flurry of recent industry acquisitions ...

Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas

(Date:5/22/2013)... Margate City, NJ (PRWEB) May 22, 2013 ... from solved. In some states, up to twenty-seven percent ... half of all bankruptcies of private citizens in the U.S. ... medical care also affects prescription drugs, meaning that many patients ... doctor, or even get them filled at all. That's ...

(Date:5/22/2013)... Beginning Aug. 22, teens are invited ... Spirit of Innovation Challenge . The annual program ... and open to students ages 13 - 18 from ... Challenge celebrates the life and entrepreneurial spirit of astronaut ... The program challenges teens to work in teams of ...

(Date:5/22/2013)... May 22, 2013 The 2013 release of ... is the largest change to hit the field of mental ... is will help prepare for the release with a Webinar ... been trained knowing no other diagnostic scheme besides the now ... manual will be released worldwide. In honor of this event, ...

(Date:5/22/2013)... May 22, 2013 Abadir Associates, a ... treatments for optimal results, is offering a new technique ... neck. The practice has successfully treated multiple patients ... “Basically, this approach is for women who want to ... dermatologist Dr. Michelle Abadir of Abadir Associates. ...

(Date:5/22/2013)... May 22 2013 - Research presented today shows ... in rats similar to those produced by drugs ... presented by addiction expert Francesco Leri, Associate Professor ... University of Guelph, suggest food addiction could explain, ... These results were presented at the 2013 ...

Breaking Medicine News(10 mins):Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2 Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2 Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2 Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2 Health News:Addiction to unhealthy foods could help explain the global obesity epidemic 2

[0] Lyrica Discount Cards Now Available From MedicationDiscountCard.com [0] Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date [0] What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 [0] Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative [0] Addiction to unhealthy foods could help explain the global obesity epidemic

... the standard treatment regimen for hepatitis C significantly increases the ... to a research report published Monday in the online edition ... team, led by Paul Kwo, M.D., of Indiana University School ... treatment,s effectiveness when given for 48 weeks in one treatment ...

... by researchers at the Bradley Hasbro Children,s Research Center ... some of the well-documented ethnic disparities in pediatric asthma. ... children in the study tended to think they were ... tests actually revealed normal lung function. According to ...

... Adding a direct acting anti-viral drug to the standard ... in the most difficult to treat patients, according to a ... journal The Lancet . The research team, led ... reported that adding the drug nearly doubled the treatment,s effectiveness ...

... The University of Colorado College of Nursing has been ... Health and Human Services, Health Resources and Services Administration ... to provide leadership for high quality healthcare in rural ... a competitively awarded grant to i-LEAD, Innovation in Leadership ...

... Reporter , FRIDAY, Aug. 6 (HealthDay News) -- "Locally grown" ... It,s a concept that has made many Americans scan their ... been raised nearby. But are locally grown foods necessarily ... grown locally will be much healthier; others, not so much. ...

... 2010 SIRIUS XM Radio (NASDAQ: SIRI) today announced ... Doctor Radio Reports: Understanding Autism - Looking for Answers, ... Perri Peltz on which a panel of world-class doctors, ... the latest research and treatment options for autism and ...

Cached Medicine News:Health News:New antiviral drug shows promise for dramatic improvement in hepatitis C treatment 2 Health News:New antiviral drug shows promise for dramatic improvement in hepatitis C treatment 3 Health News:Latino children with asthma less accurate in determining their lung function 2 Health News:New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment 2 Health News:New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment 3 Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 2 Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 3 Health News:'Locally Grown' May Mean Healthier, But Not Always 2 Health News:'Locally Grown' May Mean Healthier, But Not Always 3 Health News:Sirius XM to broadcast 'Doctor Radio Reports: Understanding Autism -- Looking for Answers' 2

New antiviral drug shows promise for dramatic improvement in hepatitis C treatment Latino children with asthma less accurate in determining their lung function New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment College of Nursing awarded grant for nursing leadership in rural and underserved areas 'Locally Grown' May Mean Healthier, But Not Always Sirius XM to broadcast 'Doctor Radio Reports: Understanding Autism -- Looking for Answers'

... The Summit SI Spinal Fixation ... for rigid posterior fixation of ... spine. The simplicity and versatility ... optimize the construct based on ...

OctaFix is designed specifically to provide stability and fixation where it is most needed....

...

Medicine Products:

Summit SI Spinal Fixation System Octafix Adson Cranial Rongeur Bateman Rongeur